CervoMed Inc. Files 8-K
Ticker: CRVO · Form: 8-K · Filed: Nov 27, 2024 · CIK: 1053691
| Field | Detail |
|---|---|
| Company | Cervomed Inc. (CRVO) |
| Form Type | 8-K |
| Filed Date | Nov 27, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, company-update
TL;DR
CervoMed filed an 8-K on 11/27/24. Nothing major, just standard SEC stuff.
AI Summary
CervoMed Inc. filed an 8-K on November 27, 2024, reporting other events and financial statements. The company, formerly known as Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus Media Group, Inc., is incorporated in Delaware and headquartered in Boston, MA.
Why It Matters
This 8-K filing indicates a routine update or event disclosure by CervoMed Inc. to the SEC, providing transparency to investors about the company's status.
Risk Assessment
Risk Level: low — This filing is a standard 8-K for 'Other Events' and financial statements, not indicating any immediate material adverse events.
Key Numbers
- 001-37942 — SEC File Number (Identifies the specific SEC filing for CervoMed Inc.)
- 30-0645032 — IRS Employer Identification No. (Tax identification number for CervoMed Inc.)
Key Players & Entities
- CervoMed Inc. (company) — Registrant
- Diffusion Pharmaceuticals Inc. (company) — Former company name
- RestorGenex Corp (company) — Former company name
- Stratus Media Group, Inc (company) — Former company name
- 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 (location) — Principal executive offices address
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the excerpt.
When was CervoMed Inc. previously known as Diffusion Pharmaceuticals Inc.?
The date of the name change from Diffusion Pharmaceuticals Inc. to CervoMed Inc. is not explicitly stated, but the filing lists it as a former company.
What is the primary business of CervoMed Inc. according to its SIC code?
CervoMed Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where are CervoMed Inc.'s principal executive offices located?
CervoMed Inc.'s principal executive offices are located at 20 Park Plaza, Suite 424, Boston, Massachusetts 02116.
What is the fiscal year end for CervoMed Inc.?
CervoMed Inc.'s fiscal year ends on December 31st.
Filing Stats: 429 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-11-27 16:01:58
Key Financial Figures
- $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market
Filing Documents
- crvo20241127_8k.htm (8-K) — 27KB
- ex_752882.htm (EX-99.1) — 14KB
- cervomed.jpg (GRAPHIC) — 7KB
- 0001437749-24-036335.txt ( ) — 185KB
- crvo-20241127.xsd (EX-101.SCH) — 3KB
- crvo-20241127_def.xml (EX-101.DEF) — 11KB
- crvo-20241127_lab.xml (EX-101.LAB) — 15KB
- crvo-20241127_pre.xml (EX-101.PRE) — 11KB
- crvo20241127_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On November 27, 2024, CervoMed Inc. announced that its oral investigational drug neflamapimod has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of frontotemporal dementia. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued November 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 27, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer & General Counsel 3